Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial
The University of Texas MD Anderson Cancer Center · Hôpital Ambroise-Paré · +23 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
773
total citations
- FWCI
- 31.51
- Percentile
- 100%
- References
- 34
Citations per year
Authors
20- MAMichael A. DaviesCorresponding
The University of Texas MD Anderson Cancer Center
- PSPhilippe Saïag
Hôpital Ambroise-Paré, Université de Versailles Saint-Quentin-en-Yvelines, Assistance Publique – Hôpitaux de Paris
- CRCaroline Robert
Université Paris-Sud
- JGJean‐Jacques Grob
Aix-Marseille Université
- KTKeith T. Flaherty
Massachusetts General Hospital
Topics & keywords
Topics
Keywords
- Dabrafenib
- Trametinib
- Medicine
- Melanoma
- Asymptomatic
- Clinical endpoint
- Oncology
- MEK inhibitor
No related works found for this paper.